A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

NCT04294667 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
321
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

UCB Biopharma SRL